Altered tolbutamide pharmacokinetics by a decrease in hepatic expression of CYP2C6/11 in rats pretreated with 5-fluorouracil

References

• Afsar A, Lee C, Riddick DS. (1996). Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. Can J Physiol Pharmacol 74:150–6
   PubMed Web of Science ®Google Scholar
• Aiba T, Horiuchi M, Makita T, et al. (2006). Peritoneal dialysis alters tolbutamide pharmacokinetics in rats with experimental acute renal failure. Drug Metab Pharmacokinet 21:291–6
   PubMed Web of Science ®Google Scholar
• Ando H, Izawa S, Hori W, et al. (2008). Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling. Theor Biol Med Model. 5:19. doi: 10.1186/1742-4682-5-19
   PubMed Web of Science ®Google Scholar
• Back DJ, Sutcliffe F, Tjia JF. (1984). Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat. Br J Pharmacol 81:557–62
   PubMed Web of Science ®Google Scholar
• Bae JW, Kim HK, Kim JH, et al. (2005). Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60:418–22
   PubMed Web of Science ®Google Scholar
• Balani SK, Nagaraja NV, Qian MG, et al. (2006). Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography tandem mass spectrometry. Drug Metab Dispos 34:384–8
   PubMed Web of Science ®Google Scholar
• Banerjee S, Das RK, Giffear KA, et al. (2015). Permanent uncoupling of male-specific CYP2C11 transcription/translation by perinatal glutamate. Toxicol Appl Pharmacol 284:79–91
   PubMed Web of Science ®Google Scholar
• Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136:215–33
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Bertrand M, Jackson P, et al. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–52
   PubMed Web of Science ®Google Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–54
   PubMed Web of Science ®Google Scholar
• Carulli N, Ponz de Leon M, Mauro E, et al. (1976). Alteration of drug metabolism in Gilbert's syndrome. Gut 17:581–7
   PubMed Web of Science ®Google Scholar
• Choi MR, Kwon MH, Cho YY, et al. (2014). Pharmacokinetics of tolbutamide and its metabolite 4-hydroxy tolbutamide in poloxamer 407-induced hyperlipidemic rats. Biopharm Drug Dispos 4:264–74
   Google Scholar
• Danenberg PV, Lockshin A. (1982). Thymidylate synthetase–substrate complex formation. Mol Cell Biochem 43:49–57
   PubMed Web of Science ®Google Scholar
• Daskalopoulos EP, Lang MA, Marselos M, et al. (2012). D2-Dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D. Mol Pharmacol 82:668–78
   PubMed Web of Science ®Google Scholar
• El-Hoseany NMA. (2012). Protective effect of captopril against 5-fluorouracil-induced hepato and nephrotoxicity in male albino rats. J Am Sci 8:680–5
   Google Scholar
• Gao J, Yan Q, Liu S, et al. (2014). Knockdown of EpCAM enhances the chemosensitivity of breast cancer cells to 5-fluorouracil by downregulating the antiapoptotic factor Bcl-2. PLoS One 9:e102590
   PubMed Web of Science ®Google Scholar
• Gilbar PJ, Brodribb TR. (2001). Phenytoin and fluorouracil interaction. Ann Pharmacother 35:1367–70
   PubMed Web of Science ®Google Scholar
• Goldstein JA, de Morais SM. (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285–99
   PubMedGoogle Scholar
• Kim SK, Novak RF. (2007). The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther 113:88–120
   PubMed Web of Science ®Google Scholar
• Konishi H, Yoshimoto T, Morita K, et al. (2003). Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats. J Pharm Pharmacol 55:143–9
   PubMed Web of Science ®Google Scholar
• Kuter DJ. (2004). In reply: low-dose warfarin prophylaxis for catheter-associated thromnosis in cancer patients. Can be safely associated with 5-fluorouracil-based chemotherapy? Oncologist 9:596
   Web of Science ®Google Scholar
• Lee CR, Pieper JA, Frye RF, et al. (2003). Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 43:84–91
   PubMed Web of Science ®Google Scholar
• Li E, Hu JP, Wang BL, et al. (2010). Effect of buagafuran on liver microsomal cytochrome P450 in rats. J Asian Nat Prod Res 12:371–81
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. (1998). Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–38
   PubMed Web of Science ®Google Scholar
• Peart GF, Boutagy J, Shenfield GM. (1987). Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. Eur J Clin Pharmacol 33:397–420
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. (2008). Dose translation from animal to human studies revisited. FASEB J 22:659–61
   PubMed Web of Science ®Google Scholar
• Ryan DE, Levin W. (1990). Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153–239
   PubMed Web of Science ®Google Scholar
• Shon JH, Yoon YR, Kim MJ, et al. (2005). Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol 59:552–63
   PubMed Web of Science ®Google Scholar
• Soucek P, Gut I. (1992). Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22:83–103
   PubMed Web of Science ®Google Scholar
• Stupans I, Richards DA, McClure MT. (1995). Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica 25:1–8
   PubMed Web of Science ®Google Scholar
• Tirumani SH, Kim KW, Nishino M, et al. (2014). Update on the role of imaging in management of metastatic colorectal cancer. Radiographics 34:1908–28
   PubMed Web of Science ®Google Scholar
• Večeřa R, Zachařová A, Orolin J, et al. (2011). Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos 32:482–7
   PubMed Web of Science ®Google Scholar
• Večeřa R, Zachařová A, Siller M, et al. (2012). The influence of rosuvastatin on liver microsomal CYP2C6 in hereditary hypertriglyceridemic rat. Neuro Endocrinol Lett 33:48–52
   PubMed Web of Science ®Google Scholar
• Vigneri P, Frasca F, Sciacca L, et al. (2009). Diabetes and cancer. Endocr Relat Cancer 16:1103–23
   PubMed Web of Science ®Google Scholar
• Wang MC, Bohmann D, Jasper H. (2005). JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell 121:115–25
   PubMed Web of Science ®Google Scholar
• Wang XS, Hu XC, Chen GL, et al. (2015). Effects of vitexin on the pharmacokinetics and mRNA expression of CYP isozymes in rats. Phytother Res 29:366–72
   PubMed Web of Science ®Google Scholar
• Wei ZG, Li GX, Huang XC, et al. (2008). Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats. World J Gastroenterol 14:2179–86
   PubMed Web of Science ®Google Scholar
• Yamao T, Nakagawa H, Furuhama K, et al. (1994). Pharmacokinetics of tolbutamide following intravenous and oral administrations in rats with obstructive jaundice. Biol Pharm Bull 17:691–5
   PubMed Web of Science ®Google Scholar
• Yao HT, Chang YW, Uramaru N, et al. (2012). Effects of Bu-Zhong-Yi-Qi-Tang on hepatic drug-metabolizing enzymes and plasma tolbutamide concentration in rats. J Ethnopharmacol 142:121–8
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Ido A, Kurihara T, et al. (2006). Serum aminotransferase activity as a predictor for estimation of total clearance of hepatically metabolized drugs in rats with acute hepatic failure. Biol Pharm Bull 29:141–5
   PubMed Web of Science ®Google Scholar
• Yokota H, Fernandez-Salguero P, Furuya H, et al. (1994). cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 269:23192–6
   PubMed Web of Science ®Google Scholar
• Zachařová A, Siller M, Spičáková A, et al. (2012). Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica 42:731–6
   PubMed Web of Science ®Google Scholar
• Zhanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41
   PubMed Web of Science ®Google Scholar